Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CDC25A | P30304 | 2/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420525 | 0.91 | AURKA (0.45) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL17594334 | 0.87 | MAPT (0.46) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL19420531 | 0.77 | CDC25B (0.43) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL1242175 | 0.77 | CES2 (0.55) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL19420537 | 0.77 | NSD2 (0.53) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL9850044 | 0.76 | NSD2 (0.61) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL1242176 | 0.73 | NSD2 (0.42) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL9562528 | 0.71 | MAPT (0.71) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| 2,3-Dibromo-1,4-Naphthoquinone SCHEMBL1240837 | 0.71 | MAPT (0.68) | MAPTPOLBRAB9AALDH1A1NPC1 | |
| 2,3-Dibromo-1,4-Naphthoquinone SCHEMBL29475349 | 0.71 | MAPT (0.68) | MAPTPOLBRAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | MAPT 2538/4885POLB 701/4885RAB9A 3443/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | MAPT 2538/4885POLB 701/4885RAB9A 3443/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | MAPT 2538/4885POLB 701/4885RAB9A 3443/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | MAPT 2538/4885POLB 701/4885RAB9A 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.